Investigation Report on China Idarubicin Market, 2010-2019
The exact cause of leukemia is yet to be identified with interior decoration pollution, ionizing radiation, drug contamination and virus infection all being the suspect. The increasing incidence of leukemia is growing in China and the number of new cases reaches 40000 each year, among which over 85% belongs to acute leukemia.
Developed by Italian Arca-mone, idarubicin is an analog of daunorubicin with higher fat solubility. Its main metabolite works by preventing DNA unwinding. In preliminary studies, idarubicin turns out to be more effective and less toxic than DNR and DXR in treating L1210 leukemia, P338 leukemia and Gross leukemia. Since 1988, Japan has conducted clinical research on acute leukemia.
As an anti-mitosiss agent, idarubicin is used in the first line treatment of acute nonlymphoblastic leukemia (ANLL) relapse remission and the second line treatment of acute lymphoblastic leukemia (ALL).
According to CRI’s market survey, idarubicin enjoys an increasing demand in China with sales value rising from about CNY 14 million in 2005 to over CNY 80 million in 2014 and CAGR during the period of 2010-2014 reaching 22%. And Pfizer Hisun Pharmaceutical Co., Ltd, Pharmacia&Upjohn (IT), Pharmacia&Upjohn (Suzhou) Pharmaceutical Co., Ltd, Pfizer Inc. (IT) and Nerviano Medical Science S.r.l. (IT) occupy the market, among which Pfizer Hisun Pharmaceutical Co., Ltd had the largest market share of over 40% for sales value in 2014.
Research has shown that autologus hematopoietic stem cell transplantation (HSCT) is an effective way to treat ALL. As idarubicin is included in autologus HSCT, its future demand is expected to be great.
Readers can get at least the following information through this report:
market size of idarubicin in China
competitive landscape of idarubicin market in China
price of idarubicin made by different enterprises in China
market outlook of idarubicin in China
The author suggests the following groups of people purchase this report:
manufacturers of antileukemic agents
investors/research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed